Alderson, Derek

Caldas, Carlos

Fitzgerald, Rebecca C

Hardwick, James S

Hardwick, Richard H

O'Donovan, Maria

Ong, Chin-Ann J

Peters, Christopher J

Rassl, Doris

Rees, Jonathan R E

Save, Vicki

Vowler, Sarah L

Zhang, Chunsheng

The incidence of esophageal and junctional adenocarcinoma has increased 6-fold in the past 30 years and 5-year survival remains approximately 20%. Current staging is limited in its ability to predict survival which has ramifications for treatment choices. The aim of this study was to generate and validate a molecular prognostic signature for esophageal adenocarcinoma

Explore Bristol Research

A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia

A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia

Abstract

Similar works

Full text

Available Versions

Explore Bristol Research